TLDR: The U.S. Food and Drug Administration (FDA) has launched ‘Elsa,’ a new agency-wide generative artificial intelligence tool designed to significantly enhance operational efficiency and accelerate various regulatory processes, including the review of new therapies.
The U.S. Food and Drug Administration (FDA) is signaling a new era of efficiency with the introduction of ‘Elsa,’ a generative artificial intelligence (AI) tool aimed at streamlining internal operations and potentially reducing approval times for new medical therapies. Launched in June 2025, ahead of schedule and under budget, Elsa is designed to assist FDA employees across various functions, from scientific reviewers to investigators.
FDA Commissioner Dr. Marty Makary has been a strong proponent of this initiative, stating that the widespread adoption of AI ‘hold[s] tremendous promise in accelerating the review time for new therapies.’ The agency had set an aggressive timeline for full AI integration across all centers by June 30, 2025, a goal that the early rollout of Elsa helps to achieve. According to the FDA, AI tools like Elsa can transform scientific-review tasks that typically require days into processes completed within minutes.
Elsa’s capabilities are extensive and are already being utilized across the agency. The tool is accelerating clinical protocol reviews, shortening the time needed for scientific evaluations, supporting safety profile assessments by summarizing adverse events, identifying high-priority inspection targets, and performing faster label comparisons. Additionally, Elsa can generate code to aid in developing databases for nonclinical applications. FDA Chief AI Officer Jeremy Walsh remarked, ‘Today marks the dawn of the AI era at the FDA with the release of Elsa, AI is no longer a distant promise but a dynamic force enhancing and optimizing the performance and potential of every employee.’
Also Read:
- U.S. Government Accelerates AI Integration Across Critical Sectors, Raising Efficiency and Safety Debates
- Stanford’s 2025 AI Index Report Highlights Unprecedented Investment and Rapid Advancements in Artificial Intelligence
Built within a high-security GovCloud environment, Elsa ensures that all information remains securely within the agency, with models explicitly not training on data submitted by regulated industries to safeguard sensitive research. While the tool promises significant advancements, the FDA is also establishing two cross-agency AI councils—one focusing on internal AI usage and another on policy governing AI’s application in FDA-regulated products—to ensure responsible implementation. Early reports noted that the model, trained on data through April 2024, provided some inaccurate or incomplete information during its initial week, but the FDA is actively updating and improving the system.
